Search Results - "Janssen, Robert"

Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years by Hyer, Randall N, Janssen, Robert S

“…Graphical abstract…”
Get full text

Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations by Hirst, Alex, Hyer, Randall N., Janssen, Robert S.

“…•HEPLISAV-B is a 2-dose Hepatitis B virus vaccine recently available in the US.•HEPLISAV-B offers earlier and higher levels of seroprotection than 3-dose…”
Get full text

Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA by MARKS, Gary, CREPAZ, Nicole, JANSSEN, Robert S

“…New HIV infections stem from people who are aware they are HIV positive (approximately 75% of infected persons in the USA) and those who are unaware of their…”
Get full text

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults by Hyer, Randall, McGuire, Darren K., Xing, Biao, Jackson, Sam, Janssen, Robert

“…Hepatitis B virus infection remains an important global public health problem. Approved alum-adjuvanted vaccines are well tolerated but require three doses and…”
Get full text

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults by Jackson, Sam, Lentino, Joseph, Kopp, James, Murray, Linda, Ellison, William, Rhee, Margaret, Shockey, Gerald, Akella, Lalith, Erby, Kimberly, Heyward, William L., Janssen, Robert S., Adams, Michael, Bolshoun, David, Bruce, Tami, Chuang, Rita, DeSantis, Donna, Fiel, Thomas, Fitzgibbons, William, Francyk, David, Geisberg, Harry, Giep, Son, Godbole, Narendra, Haas, Terry, Halpern, Stephen, Inzerello, Anthony, Jennings, William, Kaiser, Scott, Kay, Jennifer, Kirby, William, Lending, Robert, Levins, Peter, Molin, Clifford, Noss, Michael, Kotek, Larry, Reynolds, Michele, Riffer, Ernie, Schumacher, Douglas, Severance, Randall, Solano, Royce, Tejada, Albert, Tharenos, Leslie, Throne, Martin, Turner, Merle, Wolf, Thomas, Woodruff, Mark

“…•Phase 3 trial of an investigational 2 dose hepatitis B vaccine in diabetes mellitus.•2 doses of HBsAg-1018 induced significantly higher seroprotection rates…”
Get full text

Estimation of HIV Incidence in the United States by Hall, H. Irene, Song, Ruiguang, Rhodes, Philip, Prejean, Joseph, An, Qian, Lee, Lisa M, Karon, John, Brookmeyer, Ron, Kaplan, Edward H, McKenna, Matthew T, Janssen, Robert S, HIV Incidence Surveillance Group, for the

“…CONTEXT Incidence of human immunodeficiency virus (HIV) in the United States has not been directly measured. New assays that differentiate recent vs…”
Get full text

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age by Heyward, William L, Kyle, Michael, Blumenau, Joseph, Davis, Matthew, Reisinger, Keith, Kabongo, Martin L, Bennett, Sean, Janssen, Robert S, Namini, Hamid, Martin, J. Tyler

“…Highlights • Phase 3 trial of investigational hepatitis B vaccine in adults 40–70 years old. • 2 doses of HBsAg-1018 demonstrated superior seroprotection to 3…”
Get full text

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents by Richmond, Peter, Nolan, Terry, McGirr, Anthony, Napier-Flood, Fiona, Kim, Joshua, Leah, Amber, Xie, Fang, Campbell, John D., Godeaux, Olivier, Henry, Ouzama, Wood, Nicholas, Janssen, Robert S.

“…This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant…”
Get full text

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease by Girndt, Matthias, Houser, Patricia, Manllo-Karim, Roberto, Ervin, John E., Charytan, Chaim, Chow, Stephen, Symonian-Silver, Margarita, Lehrner, Lawrence, Linfert, Douglas, Shemin, Douglas, Michelsen, Ann, Xie, Fang, Janssen, Robert S.

“…•Long-term follow-up assessed persistence of antibodies to HBsAg in CKD participants.•Anti-HBs ≥ 100mIU/mL persisted for longer in HepB-CpG than HepB-Eng…”
Get full text

Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination by Janssen, Robert S., Bruxvoort, Katia, Jacobsen, Steven J., Slezak, Jeff, David, Coline, Hyer, Randall, Poland, Gregory A.

“…•Data to guide vaccination strategies are limited.•Clinical trial and real-world data were used to estimate real-world effectiveness.•Estimated real-world…”
Get full text

Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States : Implications for HIV prevention programs by MARKS, Gary, CREPAZ, Nicole, SENTERFITT, J. Walton, JANSSEN, Robert S

“…To compare the prevalence of high-risk sexual behaviors in HIV persons aware of their serostatus with that in HIV persons unaware of their status in the United…”
Get full text

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age by Janssen, Julia M, Jackson, Sam, Heyward, William L, Janssen, Robert S

“…Highlights • Phase 3 trial data of an investigational hepatitis B vaccine in subpopulations. • HBsAg-1018 induced higher seroprotection rates than HBsAg-Eng. •…”
Get full text

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease by Janssen, Robert S, Mangoo-Karim, Roberto, Pergola, Pablo E, Girndt, Matthias, Namini, Hamid, Rahman, Sophia, Bennett, Sean R, Heyward, William L, Martin, J. Tyler

“…Highlights • Phase 3 trial of investigational hepatitis B vaccine in chronic kidney disease. • HBsAg-1018 induced superior seroprotection to HBsAg-Eng. •…”
Get full text

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study by Girndt, Matthias, Plüer, Manfred, Dellanna, Frank, Michelsen, Ann K., Beige, Joachim, Toussaint, Kai, Wehweck, Hubert J., Koch, Michael, Hafezi Rachti, Syrus, Faust, Justus, Bosselmann, Hans-Peter, Witzke, Oliver, Janssen, Robert S.

“…This study compared the immunogenicity and safety of a booster dose of HepB-CpG (HEPLISAV-B® vaccine) with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in…”
Get full text

An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis by Awad, Ahmed M., Ntoso, Adu, Connaire, Jeffrey J., Hernandez, German T., Dhillon, Kiranjit, Rich, Lisa, Henderson, Heather, Lynn, Robert, Hyer, Randall N., Xie, Fang, Erby, Kimberly, Janssen, Robert S.

“…•Phase 1 study of HEPLISAV-B in hemodialysis patients.•Four doses of HEPLISAV-B induced high level of seroprotection and were well tolerated. Hemodialysis…”
Get full text

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus by Janssen, Julia M, Heyward, William L, Martin, J. Tyler, Janssen, Robert S

“…Highlights • Phase 3 trial of investigational hepatitis B vaccine in CKD and diabetes. • HBsAg-1018 induced superior seroprotection to HBsAg-Eng. • The safety…”
Get full text

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial by Waits, Alexander, Chen, Jau-Yuan, Cheng, Wei-Hong, Yeh, Jih-I, Hsieh, Szu-Min, Chen, Charles, Janssen, Robert, Lien, Chia En, Lin, Tzou-Yien

“…•Occurrence of mostly mild adverse events in older adults implies MVC-COV1901 safety.•Favorable immune responses were observed after 2 doses of…”
Get full text

Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study by Hsieh, Szu-Min, Liu, Wang-Da, Huang, Yu-Shan, Lin, Yi-Jiun, Hsieh, Erh-Fang, Lian, Wei-Cheng, Chen, Charles, Janssen, Robert, Shih, Shin-Ru, Huang, Chung-Guei, Tai, I-Chen, Chang, Shan-Chwen

“…This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVCCOV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with…”
Get full text

New developments in accelerated weathering tests for Back-contact modules by Meijers, Guido J.W., Janssen, Robert H. C, Pastukhov, Leonid, Duijnhoven, Frank van

“…Back-contact solar modules made with crystalline silicon cells are, to-date, amongst the highest peak power density devices on the market and are predicted to…”
Get full text

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir by GARCIA-LERMA, J.G, OTTEN, R.A, LIPSCOMB, J, JOHNSON, J.A, DELINSKY, D, SCHINAZI, R.F, JANSSEN, R, FOLKS, T.M, HENEINE, W, QARI, S.H, JACKSON, E, CONG, M.E, MASCIOTRA, S, LUO, W, KIM, C, ADAMS, D.R, MONSOUR, M

“…In the absence of an effective vaccine, HIV continues to spread globally, emphasizing the need for novel strategies to limit its transmission. Pre-exposure…”
Get full text